^
    1d
    DARATALL-VHR: Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD38 (CD38 Molecule)
    |
    cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1d
    GMMG-DADA: Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, University of Cologne | Recruiting --> Active, not recruiting | N=160 --> 67 | Trial completion date: Dec 2029 --> Dec 2031 | Trial primary completion date: Dec 2029 --> Mar 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1d
    NCI-2023-09969: Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Elvira Umyarova | Trial completion date: Jan 2026 --> Aug 2026 | Trial primary completion date: Jan 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    SLAMF7 (SLAM Family Member 7)
    |
    cyclophosphamide • Sarclisa (isatuximab-irfc) • Hemady (dexamethasone tablets) • UD TGFbetai NK cells
    3d
    To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Hangzhou Sumgen Biotech Co., Ltd.
    New P2 trial
    4d
    MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, University of Arkansas | Initiation date: Apr 2026 --> Jul 2026
    Trial initiation date
    |
    clonoSEQ
    |
    lenalidomide • Darzalex (daratumumab) • melphalan • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    4d
    TRANSCEND LTE: A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) (clinicaltrials.gov)
    P3, N=120, Not yet recruiting, Biogen
    New P3 trial
    |
    felzartamab (MOR202)
    5d
    Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov)
    P2, N=12, Recruiting, Memorial Sloan Kettering Cancer Center | N=25 --> 12
    Enrollment change
    |
    Sarclisa (isatuximab-irfc)
    7d
    Biomarkers of AKI in Patients Receiving Daratumumab (clinicaltrials.gov)
    P=N/A, N=20, Completed, Brigham and Women's Hospital | Recruiting --> Completed | Trial completion date: Oct 2026 --> Jan 2026 | Trial primary completion date: Sep 2026 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Darzalex (daratumumab)
    8d
    GEM-SELIBORDARA: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma (clinicaltrials.gov)
    P2, N=62, Active, not recruiting, PETHEMA Foundation | Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> Aug 2026 | Trial primary completion date: Aug 2023 --> Aug 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    bortezomib • Xpovio (selinexor) • Darzalex (daratumumab)
    9d
    Long-Term Survival with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients-A Survey from Two Italian Centers. (PubMed, Diseases)
    This study confirms the efficacy of the D-Rd combination as first-line therapy for TIE-NDMM patients, suggesting that achieving at least a PR-and particularly a VGPR-may represent a strong predictor of long-term remission and survival, even in the era of new combinations based on the use of quadruplets.
    Journal
    |
    B2M (Beta-2-microglobulin)
    |
    lenalidomide • Darzalex (daratumumab) • dexamethasone
    10d
    TAK-079-3001: A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition (2025-520825-19-00)
    P2/3, N=83, Recruiting, Takeda Development Center Americas Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    mezagitamab (TAK-079)
    17d
    Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, Emory University | Trial primary completion date: Jul 2025 --> May 2026
    Trial primary completion date
    |
    bortezomib • cyclophosphamide • Sarclisa (isatuximab-irfc)